Entrada Therapeutics develops intracellular therapeutics using its proprietary EEV™ Platform to target previously inaccessible disease-causing mechanisms within cells. The company focuses on treating devastating diseases by creating potential therapies that span from discovery to clinical stages across various therapeutic areas.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many disease-causing mechanisms occur within cells, but conventional therapeutics struggle to reach these intracellular targets effectively. This limitation hinders the development of treatments for a wide range of devastating diseases.
Solution
Entrada Therapeutics is developing a new class of intracellular therapeutics using its proprietary Endosomal Escape Vehicle (EEV™) platform. The EEV™ platform is designed to deliver therapeutic oligonucleotides to previously inaccessible disease-causing targets within cells. This platform has the potential to address the fundamental challenges of conventional intracellular therapeutics by enhancing the delivery of oligonucleotides to skeletal and cardiac muscle tissue. The company is currently developing treatments spanning from discovery to clinical stages across multiple therapeutic areas, including Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1.
Target Audience
The primary target audience includes patients suffering from devastating diseases with intracellular disease-causing mechanisms, as well as the medical community focused on developing and administering novel therapeutics.
Features
- EEV™ Platform designed to facilitate the delivery of oligonucleotides into cells.
- Focus on intracellular targets previously considered undruggable.
- Modular platform with broad potential across therapeutic areas.
- Pipeline includes programs for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1).
- Clinical studies are underway to advance potential treatments.